Loading
A phase 2 trial of Ziv-aflibercept in Ovarian cancer, Uterine sarcoma, Uterine carcinosarcoma and Leiomyosarcoma, run by National Cancer Institute (NCI), completed.
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT00390234 by National Cancer Institute (NCI), with 63 participants recorded, started 2006-09 and reaching its primary completion in 2011-09. Interventions recorded: ziv-aflibercept. Conditions recorded: Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma.
Linked to the drug Ziv-aflibercept because the registry names it among its interventions and Ovarian cancer, Uterine sarcoma, Uterine carcinosarcoma and Leiomyosarcoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
63 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2014-11-21), not from a publication
Source95% CI 0.06 to 0.32; Figures from the ClinicalTrials.gov results section (first posted 2014-11-21), not from a publication
Source95% CI 1.1 to 1.7; Figures from the ClinicalTrials.gov results section (first posted 2014-11-21), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate, Evaluated According to the RECIST Criteriaprimary | Treatment (Ziv-aflibercept) | 63 | 0 participants | - | - | link |
| Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Leiomyosaroma Group)primary | Treatment (Ziv-aflibercept) | 40 | 0.17 months | - | - | link |
| Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Carcinosarcoma Group)primary | Treatment (Ziv-aflibercept) | 22 | 1.6 months | - | - | link |
Shares Ziv-aflibercept and the tag pipeline.
Shares Ziv-aflibercept and the tag pipeline.
Shares Uterine sarcoma and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Uterine sarcoma and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.